espa logo

Professor Nicholas Katsanis, co-founder of Galatea Bio and Antithesis Therapeutics, joins IMBB as adjunct faculty | News

News
Home > News
23.04.2025

Professor Nicholas Katsanis, co-founder of Galatea Bio and Antithesis Therapeutics, joins IMBB as adjunct faculty

Dr. Katsanis is an internationally recognized scientist and executive in genetics, cell biology, and drug discovery. Over a significant career in both academia and the private sector, he has led interdisciplinary teams and international consortia to address vexing challenges in genome interpretation, mechanistic understanding of disease, and the development of novel treatments and cures. This work is reflected in >350 papers in premier journals, eleven patents, and the launch of three biotechnology companies. His work has been honored with international awards, endowed lectures, and advisory roles for governments, foundations and corporations. During this journey, he has guided teams whose skills range across the gamut of computational and experimental biology to build innovative tools and concepts that have found application in many facets of biomedicine.